Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 61 Records) |
Query Trace: Lymphoma and EML4[original query] |
---|
Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population. Journal of Cancer 2016 7 (15): 2207-2212. Zaric Bojan, Stojsic Vladimir, Panjkovic Milana, Tegeltija Dragana, Stepanov Vanesa, Kovacevic Tomi, Sarcev Tatjana, Radosavljevic Davorin, Milovancev Aleksandar, Adamidis Vasilis, Zarogoulidis Paul, Hohenforst-Schmidt Wolfgang, Trakada Georgia, Rapti Aggeliki, Perin Branisl |
The expression of SALL4 is significantly associated with EGFR, but not KRAS or EML4-ALK mutations in lung cancer. Journal of thoracic disease 2016 Oct 8 (10): 2682-2688. Jia Xiangbo, Qian Rulin, Zhang Binbin, Zhao So |
[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy ?in Non-small Cell Lung Cancer Patients in Shandong]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2017 Jan 20 (1): 14-20. Qiao Xiuli, Ai Dan, Liang Honglu, Mu Dianbin, Guo Qis |
Identification of a highly lethal V3 TP53 subset in ALK lung adenocarcinoma. International journal of cancer 2018 Sep . Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth F J, Heussel C P, Eichhorn M, Muley T, Meister M, Fischer J R, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger |
Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report. Cancer biology & medicine 2018 6 15 (2): 178-181. Zhang Ling, Li Yunxia, Zhang Shaohong, Gao Chen, Nie Keke, Ji Youx |
Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung cancer (Amsterdam, Netherlands) 2018 Apr 118 128-133. Li Yan, Zhang Tongtong, Zhang Jing, Li Wenbin, Yuan Pei, Xing Puyuan, Zhang Zhou, Chuai Shannon, Li Junling, Ying Jianmi |
Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion. OncoTargets and therapy 2018 3 11 1117-1120. Aguado Cristina, Gil Maria-de-Los-Llanos, Yeste Zaira, Giménez-Capitán Ana, Teixidó Cristina, Karachaliou Niki, Viteri Santiago, Rosell Rafael, Molina-Vila Miguel |
Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India. South Asian journal of cancer 2018 2 6 (4): 171-175. Singh Randeep, Rohtagi Nite |
Protocol to Improve Genotyping of Non-Small-Cell Lung Cancer Diagnosed Using EBUS-TBNA. Southern medical journal 2018 Oct 111 (10): 601-606. Bellinger Christina R, Sharma Deepankar, Dotson Travis, Ruiz Jimmy, Parks Graham, Haponik Edward |
Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan. International journal of clinical oncology 2019 Aug . Sakai Kosuke, Kuramoto Joji, Kojima Akitoshi, Nishimura Hiroaki, Kuwabara Yoshiki, Toda Maiko, Kobayashi Yumiko, Kikuchi Satoshi, Hirata Yusuke, Mikami-Saito Yuriko, Mikami Shintaro, Kyoyama Hiroyuki, Moriyama Gaku, Gemma Akihiko, Uematsu Kazutsu |
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cancer science 2019 8 110 (10): 3382-3390. Zhou Xiaoyun, Shou Jiawei, Sheng Jin, Xu Chunwei, Ren Shengxiang, Cai Xiuyu, Chu Qian, Wang Wenxian, Zhen Qinhong, Zhou Yuefen, Li Wenfeng, Pan Hong, Li Hongsen, Sun Tao, Cheng Huanqing, Wang Huina, Lou Feng, Rao Chuangzhou, Cao Shanbo, Pan Hongming, Fang Yo |
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. Molecular cancer therapeutics 2019 Jun . Couëtoux du Tertre Mathilde, Marques Maud, Tremblay Lise, Bouchard Nicole, Diaconescu Razvan, Blais Normand, Couture Christian, Pelsser Vincent, Wang Hangjun, Higenell Valerie, Izzi Luisa, Gambaro Karen, Hoffert Cyrla, Srivastava Archana, Spatz Alan, Rousseau Caroline, McNamara Suzan, Cohen Victor, Batist Gerald, Agulnik Jas |
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 3 14 (7): 1233-1243. Camidge D Ross, Dziadziuszko Rafal, Peters Solange, Mok Tony, Noe Johannes, Nowicka Malgorzata, Gadgeel Shirish M, Cheema Parneet, Pavlakis Nick, de Marinis Filippo, Cho Byoung Chul, Zhang Li, Moro-Sibilot Denis, Liu Ting, Bordogna Walter, Balas Bogdana, Müller Barbara, Shaw Alice |
Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib. Cancer management and research 2019 11 8191-8200. Liang Hongge, Ma Di, Xu Yan, Zhao Jing, Chen Minjiang, Liu Xiaoyan, Zhong Wei, Li Junling, Wang Mengzh |
Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055). Frontiers in oncology 2020 9 10 1216. Li Meichen, Hou Xue, Zhou Chengzhi, Feng Weineng, Jiang Guanming, Long Hao, Yang Shuang, Chen Jing, Wang Na, Wang Kaicheng, Chen Lik |
Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands) 2020 6 146 209-216. Zheng Jing, Zhu Yanping, Sun Ke, Shen Qian, Wang Yuehong, Cao He, Lizaso Analyn, Yu Bing, Lin Jing, Chen Songan, Zhou Jianya, Zhou Jianyi |
The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients. Frontiers in oncology 2020 10 726. Liu Shaokun, Huang Tanxiao, Liu Ming, He Wenlong, Zhao YingShen, Yang Lizhen, Long Yingjiao, Zong Dandan, Zeng Huihui, Liu Yuanyuan, Liao Wenting, Duan Jingxian, Gong Subo, Chen Shi |
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2020 10 149 154-161. Tao Hong, Shi Liang, Zhou Aoxue, Li Hongxia, Gai Fei, Huang Zhan, Che Nanying, Liu Z |
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. Lung cancer (Amsterdam, Netherlands) 2021 8 160 32-35. Liu Di, Xu Xinyan, Wen Junmiao, Zhang Chi, Fan M |
One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer. The oncologist 2021 Jul . Lee Youngjoo, Cho Youngnam, Park Eun Young, Park Seong-Yun, Hwang Kum Hui, Han Ji-Yo |
Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. ESMO open 2021 6 6 (3): 100161. El Shafie R A, Seidensaal K, Bozorgmehr F, Kazdal D, Eichkorn T, Elshiaty M, Weber D, Allgäuer M, König L, Lang K, Forster T, Arians N, Rieken S, Heussel C-P, Herth F J, Thomas M, Stenzinger A, Debus J, Christopoulos |
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Translational lung cancer research 2021 4 10 (3): 1525-1535. Li Jingjing, Zhang Bin, Zhang Yu, Xu Feng, Zhang Zhenfa, Shao Lin, Yan Chunhe, Ulivi Paola, Denis Marc G, Christopoulos Petros, Thomas de Montpréville Vincent, Bernicker Eric H, van der Wekken Anthonie J, Wang Changli, Yue Dongshe |
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung cancer (Amsterdam, Netherlands) 2021 12 163 7-13. Tan D S-W, Thomas M, Kim D-W, Szpakowski S, Urban P, Mehra R, Chow L Q M, Sharma S, Solomon B J, Felip E, Camidge D R, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw A |
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. Genes, chromosomes & cancer 2021 10 61 (4): 177-186. Kang Jin, Deng Qiu-Mei, Peng Kai-Cheng, Li Peng, Zhu Bao-Ting, Wang Pan, Chu Xiang-Peng, Zhong Wen-Zhao, Chen Hua-Jun, Wang Wen-Xian, Chen Hua-Fei, Rao Chuang-Zhou, Xu Chun-Wei, Yang Jin- |
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung cancer (Amsterdam, Netherlands) 2022 Jul 169 67-76. Soo Ross A, Huat Tan Eng, Hayashi Hidetoshi, Seto Takashi, Lin Chia-Chi, Ou Sai-Hong Ignatius, Kim Dong-Wan, Liu Geoffrey, Abbattista Antonello, Martini Jean-François, Hooi Wong Chew, Toffalorio Francesca, Solomon Benjamin |
Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China. International journal of cancer 2022 5 152 (1): 15-23. Su Chunxia, Zhou Juan, Qiang Huiping, Zhao Jing, Chang Qing, Ji Xianxiu, Li Jiaqi, Xie Mengqing, Chu Tianqi |
Screening of significant oncogenic changes in air pollution-related lung cancer in Chinese population. Translational cancer research 2022 2 9 (7): 4341-4353. Kanwal Madiha, Ding Xiaojie, Lin Weiming, Cao |
Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib. Translational cancer research 2022 2 8 (4): 1630-1634. Zhu You-Cai, Wan Bing, Wu Li-Xin, Li Xing-Liang, Wang Wen-Xian, Xu Chun-Wei, Zhuang Wu, Wei Jian-Guo, Du Kai- |
Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study. Cancer genetics 2022 12 270-271 32-38. Guan Maojing, Xu Jianping, Shi Qingmi |
Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review. Frontiers in oncology 2023 11 13 1227980. Qin Chen, Jingjing Zhang, Xuan Wang, Wenkang Zong, Leina Sun, Jianwen Qin, Yan Y |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: